---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-24-000009"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:52:41.103595+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health 2023 rev $9.2M (+15% YoY); cash burn halved to $15.9M

## Summary
- Q4 product revenue $2.1M flat YoY; OvaSuite volume ~5,659 tests.
- Full year 2023 OvaSuite volume 23,990 units (+12% YoY); AUP $382.
- Cash used in operations $15.9M for 2023, down 49% from $31.1M in 2022.
- Gross margin improved to 57.5% from 52.8% on lower lab/shipping costs.
- Raised $5.5M in registered direct offering post year-end; cash $2.9M at Dec 31.

## SEC filing metadata
- accession: 0000926617-24-000009
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/0000926617-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/awh-20240328x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-24-000009
- JSON: https://secwatch.observer/filing/0000926617-24-000009.json
- Plain text: https://secwatch.observer/filing/0000926617-24-000009.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue Product revenue was $2.1 million for the three months ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: Product revenue was $2.1 million for the three months ended December 31, 2023
  - Result: reported results
  source text: Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/0000926617-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.